Clinical Trial

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…

12 months ago

Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million

Press ReleaseNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNCX 470 therapeutic profile positively received…

12 months ago

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARAInitial data expected in Q4…

12 months ago

BioSenic provides further update on negotiations with its main creditors

 INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10th,…

12 months ago

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered…

12 months ago

European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys'…

12 months ago

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

12 months ago

Coloplast A/S – Announcement no. 03/2023 – Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations

Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up…

12 months ago

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional…

12 months ago